Julia Femel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Julia Femel has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
Abhinav Jaiswal
Department of Dermatology, Microbiology and Immunology, Meyer Cancer Center, Englander Institute of Precision Medicine, Weill Cornell Medicine, New York, USA
2 shared publications- Amanda W. Lund
Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA
2 shared publications Cameron Hill
Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York University Langone Health, New York, USA
2 shared publicationsDhaarini Murugan
Department of Cell, Developmental and Cancer Biology and Knight Cancer Institute, Oregon Health and Science University, Portland, USA
2 shared publicationsHaley du Bois
Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York University Langone Health, New York, USA
2 shared publicationsIan D. Dryg
Ronald O. Perelman Department of Dermatology, NYU Grossman School of Medicine, New York University Langone Health, New York, USA
2 shared publications
Latest Publications
- Open Access
Spatial protein and RNA analysis on the same tissue section using MICS technology
Spatial Biology has evolved from the molecular characterization of microdissected cells to high throughput spatial RNA and protein expression analysis at scale. The main limitation of spatial technologies so far is the inability to resolve protein and RNA information in the same histological section. Here, we report for the first time the integration of highly multiplexed RNA and protein detection on the same tissue section. We developed a new, automated, spatial RNA detection method (RNAsky™), which is based on targeted rolling circle amplification and iterative staining. We combine RNAsky with MACSima™ Imaging Cyclic Staining (MICS) based protein analysis and show compatibility with subsequent standard hematoxylin and eosin (H&E) staining. Using both, open-source tools and our recently developed software suite MACS® iQ View, we demonstrate our multiomics MICS workflow by characterizing key immune-oncology markers at subcellular resolution across normal and diseased tissues.
Open AccessSpatial protein and RNA analysis on the same tissue section using MICS technology
Spatial Biology has evolved from the molecular characterization of microdissected cells to high throughput spatial RNA and protein expression analysis at scale. The main limitation of spatial technologies so far is the inability to resolve protein and RNA information in the same histological section. Here, we report for the first time the integration of highly multiplexed RNA and protein detection on the same tissue section. We developed a new, automated, spatial RNA detection method (RNAsky™), which is based on targeted rolling circle amplification and iterative staining. We combine RNAsky with MACSima™ Imaging Cyclic Staining (MICS) based protein analysis and show compatibility with subsequent standard hematoxylin and eosin (H&E) staining. Using both, open-source tools and our recently developed software suite MACS® iQ View, we demonstrate our multiomics MICS workflow by characterizing key immune-oncology markers at subcellular resolution across normal and diseased tissues.
- 17 March 2023
- Published by Springer Nature in Nature Immunology
- Vol. 24 (4) , 729
Author Correction: T cell egress via lymphatic vessels is tuned by antigen encounter and limits tumor control
- 17 March 2023
- Published by Springer Nature in Nature Immunology
- Vol. 24 (4) , 729
Author Correction: T cell egress via lymphatic vessels is tuned by antigen encounter and limits tumor control
- 27 February 2023
- Published by Springer Nature in Nature Immunology
- Vol. 24 (4) , 664-675
T cell egress via lymphatic vessels is tuned by antigen encounter and limits tumor control
Antigen-specific CD8+ T cell accumulation in tumors is a prerequisite for effective immunotherapy, and yet the mechanisms of lymphocyte transit are not well defined. Here we show that tumor-associated lymphatic vessels control T cell exit from tumors via the chemokine CXCL12, and intratumoral antigen encounter tunes CXCR4 expression by effector CD8+ T cells. Only high-affinity antigen downregulates CXCR4 and upregulates the CXCL12 decoy receptor, ACKR3, thereby reducing CXCL12 sensitivity and promoting T cell retention. A diverse repertoire of functional tumor-specific CD8+ T cells, therefore, exit the tumor, which limits the pool of CD8+ T cells available to exert tumor control. CXCR4 inhibition or loss of lymphatic-specific CXCL12 boosts T cell retention and enhances tumor control. These data indicate that strategies to limit T cell egress might be an approach to boost the quantity and quality of intratumoral T cells and thereby response to immunotherapy.
- 27 February 2023
- Published by Springer Nature in Nature Immunology
- Vol. 24 (4) , 664-675
T cell egress via lymphatic vessels is tuned by antigen encounter and limits tumor control
Antigen-specific CD8+ T cell accumulation in tumors is a prerequisite for effective immunotherapy, and yet the mechanisms of lymphocyte transit are not well defined. Here we show that tumor-associated lymphatic vessels control T cell exit from tumors via the chemokine CXCL12, and intratumoral antigen encounter tunes CXCR4 expression by effector CD8+ T cells. Only high-affinity antigen downregulates CXCR4 and upregulates the CXCL12 decoy receptor, ACKR3, thereby reducing CXCL12 sensitivity and promoting T cell retention. A diverse repertoire of functional tumor-specific CD8+ T cells, therefore, exit the tumor, which limits the pool of CD8+ T cells available to exert tumor control. CXCR4 inhibition or loss of lymphatic-specific CXCL12 boosts T cell retention and enhances tumor control. These data indicate that strategies to limit T cell egress might be an approach to boost the quantity and quality of intratumoral T cells and thereby response to immunotherapy.